ModifiedUnitedHealthcarePolicy CS103NE.V

Prolotherapy and Platelet Rich Plasma Therapies (for Nebraska Only)

UnitedHealthcare medical policy governing coverage of prolotherapy and platelet-rich plasma therapies for members in Nebraska; defines coverage stance and lists relevant procedure codes and evidence summary.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Nebraska Only)

Policy CodePolicy CS103NE.V

Change TypeClinical evidence and references updated; archived prior version CS103NE.U

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionVerify plan-specific federal, state, or contractual prior authorization and documentation requirements before submitting requests; include documentation of failed conservative therapy and PRP/prolotherapy preparation details when applicable.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information

State-specificpolicy applies only to Nebraska

2 interventionsnamed as not medically necessary

Multiple studies (2016-2025)evidence reviewed

Several codescodes listed

low/very low

evidence quality noted

CS103NE.Upolicy version archived

Coverage Determination and Evidence Summary

Not medically necessary — general

Covered when ALL of the following are met

Not applicable: Policy states prolotherapy and platelet-rich plasma are unproven and not medically necessary for any condition or indication.

Strict non-coverage stance; no covered clinical criteria provided.

Evidence and trial eligibility

Key trial inclusion criteria and summarized evidence statements from cited RCTs and systematic reviews

Typical trial inclusion criteria: Many randomized trials enrolled adults with symptomatic disease (examples: ages ~48–80, mean ~55–63), required clinical and radiographic confirmation for the target condition (e.g., American College of Rheumatology criteria and Kellgren–Lawrence grade 2–3 for KOA), and often required persistent symptoms for ≥3 months and baseline pain thresholds (e.g., VAS ≥4).

Supports the populations studied in efficacy trials

Efficacy summaries: Trials and reviews report mixed results: some RCTs found short-term (weeks to 6 months) improvements in pain and function with dextrose prolotherapy or PRP versus saline, exercise, or other comparators, while other high-quality trials and meta-analyses found little or no difference versus placebo at 12 months; evidence heterogeneity and limited certainty are repeatedly noted.

Evidence is inconsistent across studies

Common limitations affecting generalizability: Frequent limitations include small sample sizes, short follow-up durations, heterogeneity in injection concentration/site/technique and PRP preparation, variable control groups, and lack of standardized objective structural outcomes (e.g., imaging).

Cited across multiple RCTs and systematic reviews

Comparative effectiveness

Reported comparative findings from RCTs and meta-analyses

Outcomes favoring dextrose/prolotherapy: Some RCTs and pooled analyses report that dextrose prolotherapy reduces pain and improves function versus saline or exercise (e.g., meta-analyses showing benefit at 12 weeks or short-term follow-up; individual RCTs report superiority on some pain/function measures), and network meta-analyses rank dextrose among potentially effective agents when combined with exercise for short- and long-term pain reduction.

Effects are often modest and time-limited

Outcomes not favoring dextrose/prolotherapy or PRP: Other high-quality trials and meta-analyses report little to no difference versus saline or placebo for some indications (notably a large PRP vs saline KOA RCT with no symptom or structural difference at 12 months), and systematic reviews emphasize heterogeneous results across studies and comparators.

Heterogeneous results across indications and studies

Summary of clinical evidence by indication

Evidence summaries and authors' conclusions from RCTs and systematic reviews

Lateral epicondylosis evidence: Multiple RCTs and systematic reviews report that dextrose prolotherapy (various concentrations) can reduce pain and improve function/grip strength versus saline or active controls at ~12 weeks and in some trials at longer follow-up; however, trials are small and heterogeneous and needle effects and concurrent therapies may confound results.

Supported by trials and meta-analyses of lateral epicondylitis

Rotator cuff tendinopathies evidence: Randomized trials and comparative studies report short-term pain and disability improvement with hypertonic dextrose injections and some RCTs of prolotherapy show higher proportions of good/excellent outcomes at 1 year versus exercise, but evidence is limited by small samples, variable comparators, and inconsistent longer-term effects.

Supported by RCTs and cohort studies

Temporomandibular joint disorders evidence: Systematic reviews of RCTs indicate prolotherapy reduces TMJ-related pain and can improve mouth opening and patient satisfaction versus placebo or other comparators, but heterogeneity in dextrose concentrations and short follow-up limit strength of conclusions.

Evidence summaries by indication

Summarized evidence-based findings relevant to coverage decisions

PRP for knee osteoarthritis: Randomized and pooled evidence is mixed: meta-analyses often show short- to medium-term pain/function benefits versus placebo or HA, but a large high-quality RCT (Bennell et al., n=288) found no difference in symptoms or cartilage structure at 12 months; PRP preparations are heterogeneous and evidence quality is low to mixed.

Balance of evidence does not conclusively demonstrate durable benefit

Dextrose prolotherapy for TMJ disorders: Systematic reviews and small RCTs report reductions in TMJ pain and improvements in mouth opening and function up to 12 months, but trials are small and heterogeneous, limiting certainty.

Evidence promising but limited

Autologous blood injections for TMJ hypermobility: Some trials report reduced dislocation episodes and benefit for recurrent TMJ dislocation prevention; studies are heterogeneous with bias concerns and variable protocols.

Evidence limited and variable

Evidence-based coverage considerations

Evidence summaries and conclusions from systematic reviews and trials

Knee osteoarthritis conclusions: Systematic reviews and RCTs report potential short- to medium-term improvements with PRP versus HA, corticosteroid, or placebo in some studies, and some meta-analyses suggest benefit at 12 months, but overall evidence is limited by heterogeneity, lack of standardization, and variable trial quality.

Guidance bodies call for better trials

Hip osteoarthritis conclusions: Evidence for intra-articular PRP in hip OA is limited and of low quality; network meta-analyses and HTAs did not demonstrate clinically meaningful benefit beyond placebo at up to 6 months.

Insufficient evidence for routine use

Tendinopathy and soft tissue conclusions: For some tendinopathies (e.g., lateral epicondylitis) dextrose or PRP may improve short-term pain/function; for others (Achilles, rotator cuff) evidence is inconsistent and generally low or very low quality.

Heterogeneous and low-certainty evidence

Summary medical necessity considerations

Evidence-based coverage considerations (summary of findings across conditions):

threshold":"","note":"Documentation expectations mirror trial reporting","children":[]}

Conditions with mixed or limited evidence: Plantar fasciitis: some meta-analyses report PRP superiority to corticosteroid for mid-term outcomes but with high heterogeneity; Achilles tendinopathy: evidence limited and inconclusive; lateral epicondylitis: mixed evidence with some longer-term benefit; rotator cuff: inconsistent long-term benefits of PRP.

Coverage decisions should consider indication-specific evidence strength

Adverse events and safety: PRP is associated with transient postinjection pain more commonly than comparators; serious adverse events are rare but AE reporting is inconsistent across studies.

Potential harm may influence coverage and prior-authorization review

Coverage criteria synthesized from evidence

Coverage considerations derived from evidence summaries (wounds) and clinical trials (musculoskeletal):

Wounds - Diabetic Foot Ulcers (DFU): Systematic reviews and HTAs report moderate- to low-strength evidence that adjunctive autologous PRP can increase complete wound closure for hard-to-heal DFUs compared with conventional wound therapy, but studies are heterogeneous in PRP preparation and patient selection.evidence moderate but heterogeneous

Consider adjunctive use only after adequate trial of conventional wound therapy with documentation of prior CWT and PRP protocol

Wounds - Venous Leg Ulcers (VLU) and Pressure Ulcers (PU): Evidence for VLUs and PUs is inconsistent or insufficient; small RCTs report mixed results and protocols vary widely.insufficient evidence

Not routinely covered except in clinical trial contexts or with strong justification and documentation of failed standard care

Spine and discogenic/ SIJ indications:

Coverage-relevant evidence summaries

Summary of coverage-relevant recommendations and evidence quality by indication:

Chronic wounds (DFU, VLU, PU): Systematic reviews/meta-analyses find inconclusive overall benefit of autologous PRP for chronic wounds; moderate-strength evidence supports improved complete healing for DFUs but quality is variable; NICE recommends PRP gel for diabetic foot only in research settings.

Routine coverage not supported except as adjunct in refractory DFU with documentation or within research governance

Knee osteoarthritis (KOA): Guidelines differ: AAOS (2022) notes possible benefit based on low-quality evidence and calls for better trials; ACR (2019) strongly recommends against PRP for knee/hip OA; VA/DoD states evidence insufficient; NICE advises use only with special arrangements for research/audit.

Inconsistent guideline recommendations reflect low and heterogeneous evidence

Hip and glenohumeral OA: Professional guidance finds evidence lacking to recommend routine PRP for hip or glenohumeral OA; position statements do not support routine clinical use for advanced arthritis.

Routine use not supported

UnitedHealthcare considers prolotherapy and platelet-rich plasma (PRP) therapies to be not medically necessary for any condition or indication due to insufficient evidence of efficacy. This policy explicitly lists both modalities as unproven and not covered under the stated medical necessity criteria.

Clinical trials and systematic reviews that inform this policy frequently applied trial-specific exclusion or enrollment boundaries. Examples include restriction to Kellgren–Lawrence radiographic grades (many KOA trials enrolled participants with grade 2–3 disease), exclusion of very mild (grade 1) and very severe (grade 4) osteoarthritis in some studies, and requirements for persistent symptoms (typically ≥3 months) or minimum baseline pain thresholds. Several trials also excluded patients with large effusions or recent intra‑articular corticosteroid injections; the large Bennell et al. PRP RCT specifically enrolled adults with symptomatic medial KOA meeting these radiographic criteria.

Multiple systematic reviews and evidence assessments conclude that the overall quality of evidence for prolotherapy and PRP is low or inconsistent. Reviews of lateral epicondylosis, tendinopathies, and soft-tissue injuries noted small trials, short follow-up, and heterogeneity in methods; evidence syntheses therefore call for larger, better‑designed randomized trials before definitive conclusions about clinical effectiveness can be drawn.

A recurrent reason cited across the evidence base for excluding or not covering these therapies is the lack of standardization. PRP and prolotherapy studies vary in preparation methods, platelet or dextrose concentrations, injection technique, number/timing of injections, and outcome measures. That heterogeneity, combined with small and methodologically limited trials, reduces confidence in pooled estimates of benefit and is a stated rationale for noncoverage in many evidence reviews.

Systematic reviews frequently conclude that current evidence is insufficient to recommend PRP for many indications. For knee osteoarthritis, meta-analyses report mixed findings with low-quality evidence and call for further research to identify optimal formulations and patient subgroups. For soft-tissue and tendon indications, Cochrane and other reviews summarize very‑low to low certainty evidence and do not support routine recommendation of PRP as standard care.

The document excerpts do not provide an explicit list of procedural or diagnosis-based exclusions beyond the overall noncoverage stance. Instead, systematic reviews and trials describe limitations and study-specific eligibility criteria; no separate procedural or diagnostic exclusion table is presented in the cited excerpts.

For chronic wounds, including venous leg ulcers and other wound types, routine use of PRP is not supported by conclusive evidence. Assessments (ECRI, Hayes, and systematic reviews) report heterogeneous protocols and inconsistent outcomes; although some data suggest PRP may increase complete closure rates for diabetic foot ulcers, evidence for routine PRP use across wound types is limited and lacks standardized application protocols.

The National Institute for Health and Care Excellence (NICE) advises that autologous PRP gel should not be offered for diabetic foot problems except as part of a clinical trial, reflecting the need for research‑quality governance when PRP is used for diabetic foot indications.

This Medical Policy is informational and does not replace plan benefit contracts. Coverage decisions are governed by the applicable federal, state, or contractual benefit terms; plan‑specific prior authorization rules or exclusions may apply and should be verified before providing or billing for prolotherapy or PRP services.

Given the overall insufficiency and heterogeneity of the evidence, UnitedHealthcare regards prolotherapy and PRP as unproven and not medically necessary for any condition. This policy reflects the balance of evidence assessments and randomized trials showing inconsistent or absent clinically meaningful benefit across many indications.

While many excerpts summarize study findings, they do not present a separate, definitive policy‑level statement beyond the evidence summaries and conclusions. The explicit policy-level determination that these therapies are not medically necessary is stated elsewhere in the document rather than embedded in individual evidence excerpts.

Authors of multiple reviews and trials repeatedly note that further investigation is needed. Common limitations cited include small sample sizes, heterogeneity in preparations and techniques, short follow-up durations, and inconsistent outcome reporting—factors that constrain confidence in current efficacy and safety conclusions.

A large, high‑quality randomized controlled trial (Bennell et al., n = 288) found no difference between intra‑articular PRP and saline placebo for symptoms or medial tibial cartilage volume at 12 months in participants with symptomatic, mild–moderate medial knee osteoarthritis, providing high‑quality evidence that does not support routine PRP use in that population.

Evidence for other joint and soft‑tissue indications is similarly inconclusive: network meta-analyses and systematic reviews report no clinically meaningful benefit for hip injections up to 6 months and find low‑ to very‑low quality evidence for many ligament and tendinopathy indications, limiting support for routine PRP use in these settings.

Given the low-to-very-low certainty of evidence, inconsistency between trials, and lack of consistent long‑term benefit, routine use of PRP as a first‑line therapy is not supported. Consensus across evidence reviews is that PRP should not replace established conservative or standard-of-care treatments without stronger supporting data.

Professional society guidance reflects the limited evidence base: AAOS notes limited evidence and calls for better trials before routine use for rotator cuff and glenohumeral OA indications, while the American College of Rheumatology/Arthritis Foundation 2019 guideline strongly recommends against PRP for knee and hip osteoarthritis.

Specifically, the American College of Rheumatology/Arthritis Foundation 2019 guideline issues a strong recommendation against PRP treatment in patients with knee and/or hip osteoarthritis, underscoring guideline-level opposition to routine PRP use for these OA indications.

Procedure and Supply Codes

Referenced procedure/supply codesmixed

0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication (includes as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
M0076	Prolotherapy.
P9020	Platelet rich plasma, each unit.

Covered CPT Codes, Not Covered, Experimental, Cosmetic, Presumptivemixed

No codes listed

Dextrose concentrations used in trials — reported ranges

Reported dextrose concentrations in trials5%, 15%, 25%, 50%

Typical delivery volumes reported5 mL intra-articular (example: 5 mL of 50% dextrose in KOA RCT)

Common dosing schedulesSingle or multiple injections given weekly to monthly (examples: weekly for 3 weeks; injections at weeks 0, 3, 6)

Trial heterogeneity noteConcentration, injection site, and technique varied across studies, limiting comparability

Prior Authorization, Documentation, and Billing Guidance

Billing Rule

Code list and prior authorization implication — inclusion does not imply coverage

Applicable procedure and diagnosis codes are provided for reference only. Inclusion of a code does not imply coverage, reimbursement, or guarantee of payment. Benefit coverage is determined by federal, state, or contractual requirements and applicable law; plan-specific prior authorization and billing rules may apply.

Codes referenced in policy: 0232T (PRP injection, any site), G0460 (autologous PRP for nondiabetic chronic wounds), G0465 (autologous PRP for diabetic chronic wounds using FDA-cleared device), M0076 (Prolotherapy), P9020 (Platelet rich plasma, each unit)

Note

Prior authorization — not specified in this excerpt

This policy excerpt does not specify a uniform prior authorization requirement for prolotherapy or PRP across all UnitedHealthcare plans. Providers should not assume prior authorization is or is not required based solely on this document.

Key Terms and Concepts

BACKGROUND — Prolotherapy and PRP overview

Prolotherapy definitionInjection of substances (e.g., dextrose, saline, sarapin, procaine, lidocaine, PRP, or autologous stem cells) to stimulate a mild inflammatory response and promote growth of new ligament or tendon fibers to repair injured connective tissue.

PRP overviewPlatelet‑rich plasma (PRP) is an autologous blood preparation with a high platelet concentration containing platelet‑derived growth factors and cytokines intended to stimulate tissue regeneration and repair; preparations are not standardized and vary in platelet and white blood cell concentrations.

MechanismProlotherapy aims to 'trick' the body into healing via directed injections causing localized inflammation and tissue rebuilding; PRP delivers growth factors to tissues with low healing potential to promote regeneration.

Standardization concernPRP preparations exhibit wide variability in composition and preparation methods, which may affect clinical outcomes and interpretation of studies.

Policy Version and Changes

2026-02-01policy_revisionLatest

Updated Clinical Evidence and References sections; archived prior policy version CS103NE.U

The policy was revised and the previous version (CS103NE.U) was archived on 02/01/2026. The Clinical Evidence and References sections were updated to reflect current information; reviewers and providers should reference the most recent policy text and applicable plan documents when making coverage determinations.

The policy record notes an update to the Clinical Evidence and References sections on 02/01/2026. Users should consult the policy history and confirm the effective date and any archived versions when reviewing coverage guidance.

Policy Summary

PayerUnitedHealthcare

PolicyProlotherapy and Platelet Rich Plasma Therapies (for Nebraska Only)

Policy CodePolicy CS103NE.V

Change TypeClinical evidence and references updated; archived prior version CS103NE.U

Effective DateFeb 1, 2026

Next Review DateN/A

SourceLink

On This Page

Supported by TMJ systematic reviews

Lower-limb tendinopathies evidence: Observational studies and some RCTs report pain reduction and patient-reported improvement for Achilles tendinopathy and plantar fasciitis with PRP or prolotherapy, but randomized evidence is limited and systematic reviews conclude results are inconsistent and of low quality.

Supported by Achilles/plantar fasciitis reviews

Prolotherapy for lower-limb tendinopathies: Systematic reviews and observational studies report pain reduction and satisfaction for Achilles and other tendinopathies, but randomized long-term data are limited and methodological quality is variable.

Insufficient high-quality RCT evidence for routine coverage

Surgical augmentation conclusions: Current evidence does not support routine benefit of PRP augmentation for arthroscopic meniscal repair or improving long-term ACLR outcomes; limited short-term pain/function signals exist in some studies.

No consistent long-term advantage demonstrated

Safety conclusions: Serious adverse events are uncommon across studies, but PRP is associated with higher rates of transient postinjection pain and, in foot/ankle studies, a higher overall complication rate with an estimated NNH of 13 for any complication versus comparators.

Adverse-event reporting is inconsistent

Small RCTs and prospective studies of intradiscal, facet, and SIJ PRP injections report variable short- to mid-term benefits but are limited by small sample sizes and heterogeneous methods.

limited positive RCT evidence

Consider case-by-case coverage only when conservative therapies have failed and with explicit protocol documentation and informed consent

Foot osteochondral lesions adjunctive use: A small RCT reported improved pain and function when PRP (and HA) were used adjunctively with microfracture for talar OCL, but sample size and follow-up limit generalizability.small RCT positive

May be considered as adjunct in select surgical cases with documentation of indication and prior standard care

Rotator cuff and tendon indications: AAOS and other societies note limited or insufficient evidence to support routine PRP or prolotherapy for rotator cuff tendinopathy or partial tears; liquid PRP may decrease retear rates but overall patient-reported outcome benefits are not consistently demonstrated.

Use generally limited to research or selected cases

General stance: Across indications evidence quality is low or inconsistent; guideline bodies commonly recommend PRP/prolotherapy use only in research contexts or advise against routine clinical use for several OA and tendon indications.

Coverage decisions should reflect variable guideline positions and evidence certainty

Documentation Required

Prior conservative therapy documentation

When considering prolotherapy or PRP, document that conservative therapies were attempted and failed where applicable. Trials and observational studies commonly required prior failure of standard conservative measures (e.g., physical therapy, activity modification, oral medications, orthoses) before offering prolotherapy/PRP, particularly for tendinopathies and chronic wounds.

Document prior conservative care: type, duration, and measurable outcomes (e.g., PT sessions, duration of NSAID use, orthotic use)
Record dates and providers of prior therapies and reasons for discontinuation

Prior Authorization

Prior authorization recommended in some circumstances

Given heterogeneous and low-to-moderate strength evidence across indications, consider requiring prior authorization in contexts where evidence uncertainty is greatest (e.g., musculoskeletal injections, off-label anatomic sites) and for high-cost or repeat procedures. When prior authorization is used, require documentation of prior conservative therapy and rationale for PRP/prolotherapy.

If prior authorization is requested, include: indication, prior treatments tried and dates, objective baseline measures, proposed PRP/prolotherapy protocol (preparation, volumes, concentration), and expected measurable outcomes
Consider prior authorization for procedures using non‑standard devices or when multiple treatment sessions are planned

Prior Authorization

Prior authorization of procedures/devices — device and regulatory considerations

Procedures and devices used with prolotherapy and PRP (e.g., FDA-cleared devices for PRP preparation, device-specific kits) may be subject to FDA regulation. Prior authorization processes may need to confirm that any device used is appropriate for the intended indication and that device-specific billing aligns with coverage rules.

Verify whether PRP device is FDA-cleared for the specific indication (e.g., G0465 language for diabetic wounds)
Document device make/model and any regulatory clearances when submitting authorization requests

Prior Authorization

Verify plan-specific prior authorization and benefit rules

Always verify plan- and state-specific prior authorization and coverage requirements before delivering prolotherapy or PRP. This policy is informational and may not reflect unique federal, state, or contractual mandates that govern coverage.

Check member-specific benefits and medical necessity rules in the applicable UnitedHealthcare plan
Confirm any state or federal mandates that may require coverage despite policy findings

Note

No explicit authorization or coding/coverage triggers provided in this excerpt

This document excerpt does not provide explicit operational authorization triggers, nor does it list specific claim denial codes or automated billing edits. Absence of such details here does not mean none exist at the plan level; providers should consult payer portals and business rules.

Documentation Required

PRP standardization concerns — ensure comprehensive procedural documentation

PRP preparations and application methods are heterogeneous across studies. Lack of standardization in PRP formulation, concentration, volume, leukocyte content, and application technique can affect clinical interpretation and may lead to denials if documentation is insufficient.

Provide detailed PRP preparation protocol: leukocyte-poor vs leukocyte-rich, centrifugation steps, platelet concentration, total volume administered
Document whether an FDA-cleared PRP device was used and include device details when applicable

Denial Risk

Complication risk may affect authorization — site-specific safety signals

Reported complication rates for PRP vary by anatomic site. Notably, foot and ankle studies documented higher post-injection pain and a calculated number-needed-to-harm (NNH) of 13 for any complication versus comparators. Increased complication risk may influence authorization and utilization management decisions.

Document anticipated risks and prior counseling regarding post-injection pain and other potential complications in the medical record and consent form
Consider closer review or prior authorization for foot/ankle PRP due to higher observed post-injection pain

Denial Risk

Evidence limitations may trigger denials — ensure robust supporting documentation

Heterogeneous, low- to moderate-quality evidence and inconsistent study protocols create grounds for coverage denials when clinical benefit is not clearly demonstrated. Lack of standardized reporting of PRP preparation, variable patient selection, and small or uncontrolled studies contribute to uncertainty.

When submitting for review, include high-quality supporting evidence where available (RCTs, systematic reviews) and detailed protocol and outcome measures
Be prepared for denials when documentation lacks objective baseline measures or when indications are outside supported contexts

Note

Benefit-specific governance — consider research/oversight arrangements for select indications

Certain benefits or uses of PRP may require governance or special arrangements (e.g., enrollment in research, institutional oversight) before provision. NICE recommends use with special arrangements for clinical governance, consent, and audit in knee OA; similar expectations may be applied in some plans.

For knee OA or other indications with limited evidence, consider offering PRP only within approved research protocols or with documented governance and consent processes
Document informed consent that outlines uncertainty of benefit and alternatives

Documentation Required

Coding reference and documentation note; suggested clinical documentation elements

Suggested clinical documentation elements to include with any prior authorization or coverage review: clear indication and anatomic site; objective baseline measures; prior conservative treatments and outcomes; PRP/prolotherapy preparation and administration details; number and frequency of planned treatments; and validated outcome measures with planned follow-up timepoints.

Indication and site (e.g., knee OA Kellgren-Lawrence grade), baseline pain/function scores (WOMAC, VAS, IKDC, etc.)
Prior conservative therapies and dates, imaging reports, and failure rationale
PRP/prolotherapy specifics: preparation method, platelet concentration, leukocyte content, volume, number of injections, image guidance use
Planned outcome measures and follow-up schedule (e.g., WOMAC at baseline, 2, 6, and 12 months)
Informed consent documentation when uncertainty of benefit exists

Documentation Required

Imaging documented in trials and baseline objective measures

Imaging and objective baseline measurements were commonly used in trials and are expected in documentation for review: ultrasound guidance during injections, MRI cartilage assessment in KOA trials, and radiographic grading (e.g., Kellgren-Lawrence) were frequently reported.

Include imaging reports (radiographs, MRI, ultrasound) and image-guidance details used during injection when applicable
For KOA, record Kellgren-Lawrence grade and any MRI measures referenced in the plan

Documentation Required

Documentation expectations from trials and required clinical documentation elements

Documentation expectations from clinical studies include validated outcome measures collected at baseline and at multiple follow-up points, and reporting of adverse events. Provide these when requesting authorization or appealing a denial.

Submit baseline and follow-up scores for validated instruments (WOMAC, VAS, IKDC, SPADI, DASH)
Report any adverse events observed during or after treatment and management steps taken

Documentation Required

Preferred supporting documentation and documentation for PRP in KOA

Preferred supporting documentation for PRP in knee osteoarthritis and other indications includes detailed PRP preparation methods, platelet concentration, volume administered, number of injections, device used, and consent documenting understanding of limited evidence and potential risks.

Provide a step-by-step PRP preparation description, concentration metrics, and whether leukocyte-poor or leukocyte-rich PRP was produced
Include evidence of patient enrollment in research or governance arrangements when applicable for KOA

Step Therapy

Adjunct conservative care — document concurrent and prior therapies

Adjunct conservative care was frequently used in studies (e.g., concurrent home exercise programs, physical therapy), often after failure of prior rehabilitation. Document any adjunctive therapies planned or previously used.

List concurrent or planned adjunct therapies (PT, home exercise) and prior rehab efforts with dates and outcomes
If providing PRP/prolotherapy alongside other modalities, specify how efficacy will be attributed and measured

Step Therapy

Step therapy consideration and context — require documented conservative therapy failure

Consider a stepwise requirement whereby PRP or prolotherapy is used only after failure of defined conservative therapy (step therapy). For knee OA and chronic wounds, many reviews and guidelines recommend exhausting conventional options before PRP.

Define and document the conservative therapies attempted and their durations when submitting for authorization
For wounds, ensure documentation of prolonged conventional wound therapy and failure prior to PRP use

Prolotherapy — injection of substances to promote tissue repair

DefinitionProlotherapy: injection of substances to promote growth of normal cells/tissues by stimulating an inflammatory response to strengthen and repair injured joints and connective tissue.

Common injectatesIncludes dextrose (hyperosmolar solutions), saline, sarapin, procaine, lidocaine, PRP, and autologous stem cells.

Therapeutic intentDirected injections provoke a mild inflammatory response to encourage growth of new ligament or tendon fibers and gradual tissue strengthening through repeated treatments.

Platelet-rich plasma (PRP) — autologous blood preparation with high platelet concentration

DefinitionPlatelet‑rich plasma (PRP): an autologous blood preparation with a high platelet concentration and concentrated platelet‑derived growth factors and cytokines intended to stimulate tissue regeneration and repair.

Preparation variabilityPRP preparations are heterogeneous and not standardized, varying in platelet and leukocyte content and preparation protocols.

Intended useInjected intra‑articularly or into soft tissues to augment healing in musculoskeletal conditions.

Kellgren-Lawrence grade — radiographic grading scale for OA severity

Kellgren‑Lawrence grade definitionRadiographic grading scale for osteoarthritis severity used to classify mild to severe OA; several KOA trials limited enrollment to grades 2–3 (mild to moderate).

Trial eligibility useUsed as an objective baseline radiographic criterion in high‑quality RCTs (example: inclusion of KL grade 2–3 in KOA studies).

ImplicationTrials often excluded KL grade 1 (mild) and grade 4 (severe) patients in some studies, affecting generalizability.

WOMAC — Western Ontario and McMaster Universities Osteoarthritis Index

WOMAC definitionWestern Ontario and McMaster Universities Osteoarthritis Index — validated instrument measuring pain, stiffness, and physical function in knee OA trials.

Use in trialsCommonly used as a primary or secondary outcome to assess pain and function at multiple follow‑up time points (e.g., 1, 3, 6 months).

Documentation recommendationTrials and documentation often include baseline and follow‑up WOMAC scores to support outcome assessment.

Dextrose prolotherapy (DPT/HDP) — injection of hypertonic dextrose solutions

Dextrose prolotherapy (DPT/HDP) definitionInjection of hypertonic dextrose solutions into entheses, tendons, bursae, periarticular, or intra‑articular tissues intended to provoke a local healing response and improve pain and function.

Concentrations usedTrials reported various concentrations (e.g., 5%, 15%, 25%, 50%) and differing dosing regimens.

Indications studiedApplied in lateral epicondylitis, knee OA, rotator cuff tendinopathy, TMJ disorders, and other soft tissue conditions in trials.

Prolotherapy (dextrose) — hyperosmolar dextrose into periarticular or intraarticular tissues

Clinical descriptionProlotherapy (dextrose): administration of hyperosmolar dextrose into periarticular or intra‑articular tissues to reduce pain and improve function by stimulating a repair response.

Evidence summarySystematic reviews and RCTs report mixed results across indications, with some trials showing clinically relevant improvements and others showing no difference vs saline or alternative treatments.

Common limitationsHeterogeneity in concentration, injection technique, and outcome measures across studies limits definitive conclusions.

Platelet-rich plasma (PRP) — autologous blood product; preparations vary

PRP definition (procedural)Platelet‑rich plasma (PRP) is an autologous blood product concentrated for platelets and injected intra‑articularly or into soft tissues to promote healing.

Preparation variabilityPreparations vary across studies (e.g., leukocyte‑rich vs leukocyte‑poor, activated vs nonactivated), with inconsistent reporting of concentration and volume.

Study implicationsHeterogeneity in PRP protocols complicates comparison of efficacy and safety across trials.

PRP heterogeneity — variation in preparation protocols and injection methods

PRP heterogeneityPRP preparation protocols vary widely (leukocyte‑rich vs leukocyte‑poor), as do injection methods, number and timing of injections, volume, and activation status, leading to inconsistent study results.

Reporting deficitsMany studies lack standardized reporting of PRP concentration, leukocyte content, and preparation technique.

Effect on evidenceLack of standardization limits pooling of results and reduces certainty of efficacy and safety conclusions.

PRP — autologous blood-derived concentrate; studies vary in leukocyte content

PRP clinical descriptionPRP is an autologous blood‑derived concentrate used in musculoskeletal injections; studies report variation in leukocyte content, activation, volume, and administration technique.

Evidence qualitySystematic reviews note very‑low to low certainty evidence across many soft tissue and joint indications due to small trials and heterogeneity.

Safety noteMost studies report PRP as generally safe and well tolerated, but higher rates of transient post‑injection pain have been observed in some contexts.

Common outcome measures — VAS, AOFAS, FFI, ASES, Constant, ODI

Common outcome measures listedVAS (pain), AOFAS (foot/ankle), FFI (Foot Function Index), ASES and Constant (shoulder function), ODI (low back disability).

Use in trialsThese validated instruments are commonly used at baseline and follow‑up to quantify pain and function across indications.

Documentation recommendationTrials often require baseline and follow‑up scores for these measures to support outcome assessment and authorization documentation.

PRP formulations and routes — intradiscal, intra-articular, topical/gel, other

PRP formulations and routesPRP has been prepared and administered in varying formulations and routes including intradiscal, intra‑articular, topical/gel, and injected liquid applications.

Indication‑specific routesIntradiscal PRP has been studied for discogenic low back pain; intra‑articular PRP for OA and joint pathology; topical/gel PRP for some wound applications.

Protocol variabilityNumber and timing of injections vary (single vs multiple injections; weekly to monthly intervals), affecting comparability.

Prolotherapy/PRP procedural classification and regulatory note

Procedural classificationProlotherapy and PRP are procedural injection therapies; the agents/devices used as part of these procedures may be subject to FDA regulation, but the procedures themselves are not FDA‑regulated.

Regulatory noteAgents such as dextrose and lidocaine are FDA‑approved for injection but their use for prolotherapy is off‑label; devices used to prepare PRP may have separate FDA status.

Coverage implicationFDA approval of an agent or device does not by itself determine coverage; contractual and plan‑specific rules govern benefit determinations.

NICE IPG references — interventional procedures guidance citations

NICE IPG referencesNICE interventional procedures guidance cited for autologous blood injection for tendinopathy (IPG438) and PRP injections for knee OA (IPG637).

Guideline implicationNICE guidance recommends PRP for certain indications only with special arrangements or within research contexts (e.g., knee OA IPG637).

Other referencesMultiple professional society documents and systematic reviews are cited to contextualize evidence quality and coverage considerations.